Drug
U 95666E clinical trials
Also written sumanirole.
- studies test it
- 3
- open now
- 0
- in phase 3
- 3
- first study started
- 2000
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
3 studies that test it; most in 2000 (1)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses U 95666E is read from its arms, and is right about nine times in ten.
Testing it · 3
- Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's DiseaseTerminatedPhase 3PfizerNCT00036205Written as sumanirole
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseCompletedPhase 3PfizerNCT00058838Written as sumanirole
- Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.CompletedPhase 3PfizerNCT00036218Written as sumanirole
Codes
What other systems call U 95666E · ClinicalTrials.gg INT004022
- MeSH (NLM) C108539U 95666EOne source NLM
- UNII (FDA) 2OI87T3R1BSUMANIROLE MALEATEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C108539 | U 95666E | One source NLM |
| UNII (FDA) | 2OI87T3R1B | SUMANIROLE MALEATE | Confirmed FDA, NLM |
Also registered as sumanirole (UNII 3E93IV1U45).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.